Medical Developments International Crescita futura
Future criteri di controllo 4/6
Medical Developments International is forecast to grow earnings and revenue by 93.1% and 14.4% per annum respectively. EPS is expected to grow by 94.3% per annum. Return on equity is forecast to be 7% in 3 years.
Informazioni chiave
93.1%
Tasso di crescita degli utili
94.3%
Tasso di crescita dell'EPS
| Pharmaceuticals crescita degli utili | 54.6% |
| Tasso di crescita dei ricavi | 14.4% |
| Rendimento futuro del capitale proprio | 7.0% |
| Copertura analitica | Low |
| Ultimo aggiornamento | 25 Oct 2024 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Positive Sentiment Still Eludes Medical Developments International Limited (ASX:MVP) Following 27% Share Price Slump
May 13
Is Medical Developments International (ASX:MVP) In A Good Position To Invest In Growth?
May 03Why Investors Shouldn't Be Surprised By Medical Developments International Limited's (ASX:MVP) 28% Share Price Plunge
Mar 11Medical Developments International Limited (ASX:MVP) Soars 28% But It's A Story Of Risk Vs Reward
Jan 16Will Medical Developments International (ASX:MVP) Spend Its Cash Wisely?
Jan 03Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?
Aug 09We're Keeping An Eye On Medical Developments International's (ASX:MVP) Cash Burn Rate
Apr 24Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?
Jul 04Some Analysts Just Cut Their Medical Developments International Limited (ASX:MVP) Estimates
Mar 04Medical Developments International Limited (ASX:MVP) Analysts Just Slashed This Year's Estimates
Mar 05If You Had Bought Medical Developments International (ASX:MVP) Shares Five Years Ago You'd Have Earned 56% Returns
Feb 07Don't Ignore The Fact That This Insider Just Sold Some Shares In Medical Developments International Limited (ASX:MVP)
Dec 16Medical Developments International Limited's (ASX:MVP) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?
Dec 10
Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 6/30/2027 | 55 | 4 | 4 | 7 | 1 |
| 6/30/2026 | 48 | 0 | 5 | 7 | 1 |
| 6/30/2025 | 41 | -4 | 1 | 3 | 1 |
| 6/30/2024 | 33 | -41 | -14 | -11 | N/A |
| 3/31/2024 | 33 | -30 | -17 | -12 | N/A |
| 12/31/2023 | 34 | -19 | -21 | -15 | N/A |
| 9/30/2023 | 33 | -12 | -23 | -16 | N/A |
| 6/30/2023 | 32 | -6 | -24 | -16 | N/A |
| 3/31/2023 | 29 | -4 | -22 | -16 | N/A |
| 12/31/2022 | 26 | -2 | -20 | -15 | N/A |
| 9/30/2022 | 24 | -7 | -18 | -13 | N/A |
| 6/30/2022 | 22 | -12 | -16 | -11 | N/A |
| 3/31/2022 | 22 | -16 | -17 | -10 | N/A |
| 12/31/2021 | 22 | -19 | -17 | -10 | N/A |
| 9/30/2021 | 24 | -16 | -16 | -9 | N/A |
| 6/30/2021 | 25 | -13 | -15 | -9 | N/A |
| 3/31/2021 | 25 | -7 | -14 | -8 | N/A |
| 12/31/2020 | 24 | -1 | -13 | -6 | N/A |
| 9/30/2020 | 23 | 0 | -11 | -3 | N/A |
| 6/30/2020 | 23 | 0 | -9 | 0 | N/A |
| 3/31/2020 | 22 | 1 | -8 | 1 | N/A |
| 12/31/2019 | 22 | 1 | -8 | 1 | N/A |
| 9/30/2019 | 22 | 1 | 2 | 11 | N/A |
| 6/30/2019 | 21 | 1 | 11 | 21 | N/A |
| 3/31/2019 | 20 | 1 | 12 | 22 | N/A |
| 12/31/2018 | 19 | 0 | 12 | 23 | N/A |
| 9/30/2018 | 18 | 0 | 2 | 12 | N/A |
| 6/30/2018 | 17 | 0 | -9 | 2 | N/A |
| 3/31/2018 | 18 | 1 | N/A | 2 | N/A |
| 12/31/2017 | 18 | 2 | N/A | 3 | N/A |
| 9/30/2017 | 18 | 2 | N/A | 3 | N/A |
| 6/30/2017 | 18 | 2 | N/A | 4 | N/A |
| 3/31/2017 | 18 | 2 | N/A | 4 | N/A |
| 12/31/2016 | 18 | 2 | N/A | 4 | N/A |
| 9/30/2016 | 17 | 2 | N/A | 8 | N/A |
| 6/30/2016 | 15 | 2 | N/A | 12 | N/A |
| 3/31/2016 | 14 | 1 | N/A | 12 | N/A |
| 12/31/2015 | 12 | 1 | N/A | 13 | N/A |
| 9/30/2015 | 12 | 1 | N/A | 8 | N/A |
| 6/30/2015 | 12 | 2 | N/A | 3 | N/A |
| 3/31/2015 | 11 | 1 | N/A | 3 | N/A |
| 12/31/2014 | 10 | 1 | N/A | 3 | N/A |
| 9/30/2014 | 10 | 1 | N/A | 2 | N/A |
| 6/30/2014 | 9 | 1 | N/A | 1 | N/A |
| 3/31/2014 | 10 | 1 | N/A | 1 | N/A |
| 12/31/2013 | 10 | 1 | N/A | 0 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: MVP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).
Guadagni vs Mercato: MVP is forecast to become profitable over the next 3 years, which is considered above average market growth.
Guadagni ad alta crescita: MVP is expected to become profitable in the next 3 years.
Ricavi vs Mercato: MVP's revenue (14.4% per year) is forecast to grow faster than the Australian market (5.7% per year).
Ricavi ad alta crescita: MVP's revenue (14.4% per year) is forecast to grow slower than 20% per year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: MVP's Return on Equity is forecast to be low in 3 years time (7%).